报价延迟最少15分钟:2026/03/09 10:37 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.73 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-29.03/-4.42
|
|
企业价值
4.15M
|
| 资产负债 |
|
每股账面净值
2.05
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models. |
